Ghrelin, ghrelin

High Constitutive Signaling of the Ghrelin Receptor-Identification of a Potent Inverse Agonist

Ghrelin is a GH (GH) releasing peptide, which also has an important role as an orexigenic hormone stimulating food intake. By measuring inositol phosphate turnover or by using a reporter assay for transcriptional activity controlled by cAMP responsive elements, the ghrelin receptor showed strong, ligand-independent signaling in transfected COS-7 or HEK293 cells. Ghrelin and a number of the known non-peptide GH secretagogues acted as agonists stimulating inositol phosphate turnover further. In contrast, the low potency ghrelin antagonist, [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]-substance P was surprisingly found to be a high potency (EC50 = 5.2 nM) full inverse agonist as it decreased the constitutive signaling of the ghrelin receptor down to that observed in un-transfected cells. The homologous motilin receptor functioned as a negative control as it did not display any sign of constitutive activity; however, upon agonist stimulation the motilin receptor signaled as strongly as the un-stimulated ghrelin receptor. It is concluded that the ghrelin receptor is highly constitutively active and that this activity could be of physiological importance in its role as a regulator of both GH secretion and appetite control. It is suggested that inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

Holst B, et al. Mol Endocrinol. 2003 Aug 7 [Epub ahead of print].

[D-Lys3]-GHRP-6's antagonist activity in Ghrelin induced growth-hormone secretion in prepubertal rats

Ghrelin is a 28-amino-acid peptide, with an essential n-octanoyl modification at Ser3, that elicits growth-hormone (GH) secretion in rats and humans. At present, the mechanisms of ghrelin action and its interactions with other systems controlling GH secretion remain poorly characterized. In this context, the present study was undertaken to obtain information about ontogeny and possible gender differences in the GH-releasing activity of ghrelin, and to delineate its primary site(s) of action at the hypothalamus and/or pituitary. In addition, the interactions between ghrelin and other relevant signals in the control of GH secretion, such as excitatory amino acids (EAAs), nitric oxide (NO) and serotonin, were assessed. Experiments were carried out in infantile-prepubertal animals, when GH pulsatility is not yet established. Systemic administration of ghrelin (25 nmol/rat, i.p.) to 5-, 10- and 23-day-old male and female rats increased plasma GH levels from day 10 onwards. This action was NO dependent, since it disappeared in 23-day-old males after pretreatment with an inhibitor of NO synthase (NAME). Similarly, central infusion of ghrelin (3 nmol/rat, i.c.v.) elicited GH responses in 10- and 23-day-old animals significantly higher than after systemic administration. By contrast, in vitro challenge of pituitary tissue with increasing doses of ghrelin (10(-9)-10(-7) M) failed to enhance GH release into the incubation medium, whereas stimulation with GH-releasing hormone (GHRH; 10(-7) M) or GHRP-6 (10(-7) M) was effective. Finally, effects of ghrelin were blocked by pretreatment with MK-801 and NBQX antagonists of EAA ionotropic receptors and after manipulation of endogenous serotoninergic tone. In addition, the potent releasing activity of EAA agonists NMDA and AMPA was blunted by pretreatment with D-Lys3-GHRP-6, a selective antagonist of the cognate ghrelin receptor, i.e. the GH-secretagogue receptor. In conclusion, our results demonstrate that GH-releasing activity of ghrelin appears early in the infantile period, is NO dependent and involves a primary hypothalamic site of action. The data also demonstrate for the first time the existence of a cross-talk between ghrelin and other neurotransmitter systems, such as EAAs and serotonin, in precise control of GH secretion.

Pinilla L, et al. Neuroendocrinology 2003 Feb;77(2):83-90

Antagonism of ghrelin receptor reduces food intake and body weight gain in mice

BACKGROUND AND AIMS: Ghrelin, an endogenous ligand for growth hormone secretagogue receptor (GHS-R), is an appetite stimulatory signal from the stomach with structural resemblance to motilin. We examined the effects of the gastric peptide ghrelin and GHS-R antagonists on energy balance and glycaemic control in mice. MATERIALS AND METHODS: Body weight, fat mass, glucose, insulin, and gene expression of leptin, adiponectin, and resistin in white adipose tissue (WAT) were measured after repeated administrations of ghrelin under a high fat diet. Gastric ghrelin gene expression was assessed by northern blot analysis. Energy intake and gastric emptying were measured after administration of GHS-R antagonists. Repeated administration of GHS-R antagonist was continued for six days in ob/ob obese mice. RESULTS: Ghrelin induced remarkable adiposity and worsened glycaemic control under a high fat diet. Pair feeding inhibited this effect. Ghrelin elevated leptin mRNA expression and reduced resistin mRNA expression. Gastric ghrelin mRNA expression during fasting was increased by a high fat diet. GHS-R antagonists decreased energy intake in lean mice, in mice with diet induced obesity, and in ob/ob obese mice; it also reduced the rate of gastric emptying. Repeated administration of GHS-R antagonist decreased body weight gain and improved glycaemic control in ob/ob obese mice. CONCLUSIONS: Ghrelin appears to be closely related to excess weight gain, adiposity, and insulin resistance, particularly under a high fat diet and in the dynamic stage. Gastric peptide ghrelin and GHS-R may be promising therapeutic targets not only for anorexia-cachexia but also for obesity and type 2 diabetes, which are becoming increasingly prevalent worldwide.

Asakawa A, et al. Gut. 2003 Jul;52(7):947-52

Effects of ghrelin administered intraperitoneally (3 nmol/mouse every 12 hours for five days) on calorie intake, epididymal fat mass, gastrocnemius muscle, and blood glucose, insulin, cholesterol, triglycerides, and free fatty acid concentrations in lean mice under a high fat diet
	LF, saline	HF, saline	HF, ghrelin

Calorie intake (kcal/day)	18.83 (1.055)	23.22 (1.329)	25.94 (2.562)*
Fat pad mass(g)	0.533 (0.049)	0.797 (0.095)	1.202 (0.175)**
Skeletal musde (g)	0.337 (0.016)	0.353 (0.010)	0.340 (0.005)
Glucose (mmol/l)	7.899 (0.476)	8.393 (0.825)	8.909 (0.498)
Insulin (pmol/l)	135.0 (20.10)	177.5 (13.05)	378.0 (141.8)*
Cholesterol (mmol/l)	3.742 (0.337)	5.568 (0.497)	5.813 (0.509)**
Triglycerides (mmol/l)	0.347 (0.032)	0.305 (0.039)	0.371 (0.090)
Free fatty acids (meq/l)	1.467 (0.050)	1.623 (0.100)	1.636 (0.047)

Results are expressed as mean (SEM).
LF and HF indicate a standard diet and a high fat diet, respectively.
p<0.05, *p<0.01 between saline treated mice fed a standard diet and ghrelin treated mice fed a high fat diet.
p<0.05 between saline treated mice fed a high fat diet and ghrelin treated mice fed a high fat diet.

Chronic effects of ghrelin administered intraperitoneally (3 nmol/mouse every 12 hours for five days) on resistin gene expression in the epididymal fat mass under a high fat (HF) diet, as assessed by northern blot analysis, expressed as a percentage of physiological saline treated controls under a standard (LF) diet. Results are expressed as mean (SEM): n indicates the number of mice used, *p<0.05 between saline treated mice fed a high fat diet and ghrelin treated mice fed a high fat diet. (B) Stimulatory effects of a high fat diet for two weeks on ghrelin gene expression in the stomach of food deprived mice, as assessed by northern blot analysis, expressed as a percentage of standard diet fed controls. (Top) A representative northern blot analysis showing gastric ghrelin mRNA during fasting after a high fat diet for two weeks; *p<0.05 compared with the control group by Bonferroni�s t test. G3PDH, glyceraldehyde 3-phosphate dehydrogenase.

Effects of intraperitoneally administered [D-Lys-3]-GHRP-6 (2�200 nmol/mouse) on cumulative food intake in food deprived lean mice: *p<0.05, **p<0.01 compared with the control group by Bonferroni�s t test. (B) Effects of intracerebroventricularly administered [D-Lys-3]-GHRP-6 (0.2�20 nmol/mouse) on cumulative food intake in food deprived lean mice. ACSF, artificial cerebrospinal fluid. (C) Antagonistic effects of [D-Lys-3]-GHRP-6 administered intracerebroventricularly (20 nmol/mouse) on feeding induced by intraperitoneal injection of ghrelin (3 nmol/mouse) in non-food deprived lean mice. (D) Inhibitory effects of intraperitoneally administered [D-Lys- 3]-GHRP-6 (20�200 nmol/mouse) on the gastric emptying rate one and two hours after injection in lean mice. (E) Effects of intraperitoneally administered [D-Arg-1, D-Phe-5, D- Trp-7, 9, Leu-11] substance P (10�100 nmol/mouse) on cumulative food intake in food deprived lean mice. (F) Effects of intraperitoneally administered [D-Lys-3]-GHRP-6 (20�200 nmol/mouse) on cumulative food intake in mice with diet induced obesity who received a high fat diet for two weeks.

Acute effects of intraperitoneally administered [D-Lys-3]-GHRP-6 (200 nmol/mouse) on cumulative food intake in food deprived ob/ob obese mice: *p<0.05, **p<0.01 compared with physiological saline treated controls. (B) Chronic effects of [D-Lys- 3]-GHRP-6 administered intraperitoneally (20�200 nmol/mouse every 12 hours for six days) on body weight gain in non-food deprived ob/ob obese mice.

Effects of [D-Lys-3]-GHRP-6 administered intraperitoneally (20�200 nmol/mouse every 12 hours for six days) on food intake, epididymal fat mass, gastrocnemius muscle, and blood glucose, insulin, cholesterol, triglyceride, and free fatty acid concentrations in ob/ob obese mice


	Saline	20 nmol	200 nmol

Food intake (g/day)	4.845 (0.160)	4.527 (0.261)	4.285 (0.298)
Fat pad mass (g)	0.974 (0.066)	0.897 (0.169)	0.860 (0.086)
Skeletal muscle (g)	0.300 (0.012)	0.314 (0.009)	0.326 (0.013)
Glucose (mmolli)	13.01 (1.538)	12.06 (1.549)	7.489 (1.081)*
Insulin (pmol/1)	8294 (1676)	6242 (1628)	5481 (1304)
Cholesterol (mmol/1)	6.649 (0.346)	5.663 (0.291)	5.906 (0.565)
Triglycerides (mmol/l)	0.518 (0.049)	0.436 (0.040)	0.465 (0.068)
Free fatty acids (meq/l)	2.164 (0.075)	2.036 (0.121)	1.646 (0.078)**

p<0.05, *p<0.01 compared with physiological saline treated controls.

GHRF-6, An Agonist for Ghrelin receptor (GHS-R)

Interaction of the growth hormone releasing peptides, ghrelin and GHRP-6, with the motilin receptor in the rabbit gastric antrum
The structural relationship between the motilin and the growth hormone secretagogue receptor (GHS-R), and between their respective ligands, motilin and ghrelin, prompted us to investigate whether ghrelin and the GHS-R agonist, growth hormone releasing peptide-6 (GHRP-6), could interact with the motilin receptor. The interaction was evaluated in the rabbit gastric antrum with binding studies on membrane preparations and with contraction studies on muscle strips in the presence of selective antagonists under conditions of electrical field stimulation (EFS) or not. Binding studies indicated that the affinity (pKd) for the motilin receptor was in the order of: ghrelin (4.230.07) < GHRP-6 (5.540.08) < motilin (9.130.03). The interaction of ghrelin with the motilin receptor requires the octanoyl group. Motilin induced smooth muscle contractile responses but ghrelin and GHRP-6 were ineffective. EFS elicited on- and off-responses that were increased by motilin already at 10(-9) M, but not by 10(-5) M ghrelin. In contrast, GHRP-6 also enhanced the on- and off-responses. The motilin antagonist, GM-109, blocked the effect of GHRP-6 on the off- but not on the on-responses. Under NANC conditions the effects of motilin and GHRP-6 on the on-responses were abolished, those on the off-responses were preserved. All responses were blocked by NK1 and NK2 antagonists. In conclusion, ghrelin is unable to induce contractions via the motilin receptor. However, GHRP-6 enhances neural contractile responses, partially via interaction with the motilin receptor on non-cholinergic tachykininergic nerves, partially via another receptor that may be a GHS-R subtype on cholinergic nerves that corelease tachykinins.

Depoortere I, et al. J Pharmacol Exp Ther 2003 Feb 11; [epub ahead of print]

康肽生物科技.